Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

Abstract Aim Palivizumab has proven effective in reducing hospitalizations, preventing severe illness, improving health outcomes, and reducing healthcare costs for infants at risk of respiratory syncytial virus (RSV) infection. We aim to assess the value of palivizumab in preventing RSV infection in...

Full description

Bibliographic Details
Main Authors: Jaime E. Ordóñez, Victor M. Huertas
Format: Article
Language:English
Published: BMC 2024-04-01
Series:BMC Infectious Diseases
Subjects:
Respiratory syncytial viruses
Premature birth
Bronchopulmonary dysplasia
Congenital heart defects
Palivizumab
Respiratory sounds
Online Access:https://doi.org/10.1186/s12879-024-09300-5

Internet

https://doi.org/10.1186/s12879-024-09300-5

Similar Items